Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 10:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 9,194 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Care of Treatment Clear all
Suspended No phase listed Observational Accepts healthy volunteers

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

NCT04638751
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions
Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy
Drug · Procedure
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
10
States / cities
Orange, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 5, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

NCT04380961
View directory record Official record
Conditions
Critical Confirmed Coronavirus Disease (COVID)-19
Interventions
Sirukumab, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years to 84 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Long Beach, California • Newport Beach, California • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 5, 2026, 10:17 AM EDT
Recruiting Not applicable Interventional

Modified Multi-Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of DFU and VLUs

NCT06560502
View directory record Official record
Conditions
Diabetic Foot Ulcer, Venous Leg Ulcer, Ulcer Foot, Leg Ulcer
Interventions
Standard of Care-DFU, AmnioCore - DFU, Amnio Quad-Core - DFU, Standard of Care-VLU, Amnio Tri-Core - VLU, Amniocore Pro +
Other
Lead sponsor
Stability Biologics
Industry
Eligibility
21 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Circleville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 5, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

NCT03719131
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
Interventions
Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 5, 2026, 10:17 AM EDT
Terminated Phase 2 Interventional Results available

Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy

NCT03223662
View directory record Official record
Conditions
Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Neoplasms, Squamous Cell Carcinoma
Interventions
Chemoradiotherapy, Esophagectomy
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 5, 2026, 10:17 AM EDT
Recruiting Not applicable Interventional

Personalized Tobacco Treatment in Primary Care (MOTIVATE)

NCT05846841
View directory record Official record
Conditions
Physician's Role, Smoking Cessation, Smoking
Interventions
Precision Treatment, Usual Care
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 5, 2026, 10:17 AM EDT
Enrolling by invitation Not applicable Interventional

Population Health Management for KPNC Members With Newly Diagnosed Diabetes: A Randomized Trial of a Proactive and Augmented Initial Care Strategy

NCT06906653
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes (T2D)
Interventions
Augmented Initial Type 2 Diabetes Care
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 74 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 5, 2026, 10:17 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

NCT05372003
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Photo therapy
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 5, 2026, 10:17 AM EDT
Not yet recruiting Early Phase 1 Interventional

Preoperative Semaglutide Prior to Radical Prostatectomy

NCT07727473
View directory record Official record
Conditions
Prostate Cancer
Interventions
Semaglutide 2.4 mg
Drug
Lead sponsor
Banner Health
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 5, 2026, 10:17 AM EDT
Completed Early Phase 1 Interventional

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

NCT04057053
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Cataract
Interventions
Netarsudil 0.02% Ophthalmic Solution
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
50 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 5, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

NCT01922037
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
145
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 5, 2026, 10:17 AM EDT
Not listed Not applicable Interventional

Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer

NCT00770822
View directory record Official record
Conditions
Prostate Cancer
Interventions
HIFU (Sonablate® 500), Brachytherapy
Device
Lead sponsor
SonaCare Medical
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Naples, Florida • Myrtle Beach, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 5, 2026, 10:17 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients

NCT00157131
View directory record Official record
Conditions
Deep Partial or Full Thickness Wounds
Interventions
Fibrin Sealant, ARTISS 4IU/ml VH SD, Staples
Biological · Other
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Up to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 5, 2026, 10:17 AM EDT
Completed Not applicable Interventional

2 Phase Use Of Educational Materials In Head And Neck Cancer Center

NCT02204631
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Head and Neck Educational Handbook
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 5, 2026, 10:17 AM EDT
Withdrawn Phase 1 Interventional

Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers

NCT01353937
View directory record Official record
Conditions
Diabetic Ulcer
Interventions
AMD3100 injection + rhPDGF-BB topical
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
35 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 5, 2026, 10:17 AM EDT
Terminated Phase 3 Interventional

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

NCT04489537
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
MarzAA
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 5, 2026, 10:17 AM EDT
Withdrawn Phase 2 Interventional

REperfusion With Cooling in CerebraL Acute IscheMia II

NCT02411877
View directory record Official record
Conditions
Ischemic Stroke, Hypothermia
Interventions
Normothermia, Mild hypothermia, Trevo Pro Retriever (Stryker Corp.), Zoll Thermogard XP technology with the Quattro catheter
Procedure · Device
Lead sponsor
WellStar Health System
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 5, 2026, 10:17 AM EDT
Active, not recruiting Phase 2 Interventional

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

NCT06381154
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Fluorouracil, Irinotecan, Leucovorin, Lymph Node Biopsy, Magnetic Resonance Imaging, Oxaliplatin, Pembrolizumab, Photodynamic Therapy, Positron Emission Tomography, Questionnaire Administration, Verteporfin
Procedure · Drug · Biological + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 5, 2026, 10:17 AM EDT
Withdrawn No phase listed Observational

Prospective Evaluation Of Outcomes For Patients Undergoing Radiofrequency Ablation (RFA) Using HALO Ultra Device For Gastric Antral Vascular Ectasia (GAVE)

NCT03525366
View directory record Official record
Conditions
Gastric Antral Vascular Ectasia
Interventions
Radiofrequency ablation
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 5, 2026, 10:17 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer

NCT00020722
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC), Leukapheresis, peripheral blood stem cell transplantation (PBSCT)
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 5, 2026, 10:17 AM EDT
Not yet recruiting Not applicable Interventional

Use of a Vibration Tool for Postoperative Pain Control in Distal Radius Fractures

NCT05318729
View directory record Official record
Conditions
Distal Radius Fracture, Radius Fracture Distal, Radius; Fracture, Lower or Distal End, Postoperative Pain
Interventions
Vibration tool
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 5, 2026, 10:17 AM EDT
Completed Phase 2 Interventional

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

NCT02187302
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
CRLX101, Bevacizumab, Standard of Care (Investigator Choice)
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
38
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 5, 2026, 10:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Opioid Sparing Effect of an ISP Nerve Block on Post-Op Pain Control in Posterior Cervical Spine Surgery

NCT06570577
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Inter-semispinalis Plane Block, Opioids
Procedure · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 5, 2026, 10:17 AM EDT
Recruiting Phase 3 Interventional

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

NCT07007312
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C)
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
42
States / cities
Gilbert, Arizona • Clovis, California • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 5, 2026, 10:17 AM EDT